Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials
Publication date: October 2026 Source: European Urology Oncology, Volume 9, Issue 5 Author(s): Alexander Light, Max Peters, Archana Gopalakrishnan, Nikhil Mayor, Alex Freeman, Mark Emberton, Hashim U. Ahmed, Taimur T. Shah
Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials. // European Urology Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2588931126001586?dgcid=rss_sd_all
Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials. European Urology Oncology. https://www.sciencedirect.com/science/article/pii/S2588931126001586?dgcid=rss_sd_all
“Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials.” European Urology Oncology.
@article{article45878,
title = {Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials},
journal = {European Urology Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2588931126001586?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...